3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
83
Pancreatic Neoplasms
33
Stomach Neoplasms
32
Rectal Neoplasms
23
Colonic Neoplasms
22
Neoplasms
20
Neoplasm Metastasis
19
Esophageal Neoplasms
16
Cholangiocarcinoma
14
Adenocarcinoma Of Esophagus
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Carcinoma, Non-Small-Cell Lung
12
Burkitt Lymphoma
12
Biliary Tract Neoplasms
12
Adenocarcinoma
11
Gastrointestinal Neoplasms
7
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Ovarian Neoplasms
6
Leukemia, Biphenotypic, Acute
5
Gallbladder Neoplasms
5
Esophageal Squamous Cell Carcinoma
5
Endometrial Neoplasms
5
Advanced Solid Tumors
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Lung Neoplasms
4
Leukemia
4
Carcinoma, Renal Cell
4
Appendiceal Neoplasms
4
Urinary Bladder Neoplasms
3
Interventions
Nivolumab
3
capivasertib
2
Gemcitabine
2
Cisplatin
2
tivozanib
1
regorafenib
1
niraparib
1
neratinib
1
lutetium Lu 177 dotatate
1
fludarabine phosphate
1
fludarabine
1
encorafenib
1
durvalumab
1
copanlisib
1
cemiplimab
1
axicabtagene ciloleucel
1
avasopasem manganese
1
Valproic Acid
1
Thioctic Acid
1
Taxes
1
Receptors, Interleukin-6
1
Radiosurgery
1
RNA-Seq
1
Pemetrexed
1
Paclitaxel
1
Oxaliplatin
1
Multiparametric Magnetic Resonance Imaging
1
Leucovorin
1
Lenalidomide
1
Interleukin 1 Receptor Antagonist Protein
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
Leucovorin
×
1 year
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts